« Back
Home /
EPI-7170

EPI-7170

Item no.	HY-150102-100mg
Manufacturer	MedChem Express
CASRN	2139288-26-7
Amount	100 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	95.26
Formula	C22H28Cl3NO6S
Citations	[1]Hirayama Y, et al. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol Oncol. 2020 Oct;14(10):2455-2470.
Smiles	CC(C1=CC(Cl)=C(C(Cl)=C1)OC[C@H](O)CCl)(C2=CC=C(C=C2)OC[C@H](O)CNS(C)(=O)=O)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Product Description	EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC)[1].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	540.88
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	10 mM in DMSO
Manufacturers Target	Androgen Receptor
Pathway	Vitamin D Related/Nuclear Receptor
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time